COMMUNIQUÉS West-GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares
22/11/2024
SeaStar Medical urges stockholders to vote FOR all proxy proposals prior to the Special Meeting of Stockholders to be held November 26, 2024 DENVER, Nov. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation [...]
Result of General Meeting
22/11/2024
November 22, 2024 Biodexa Pharmaceuticals PLC (“ Biodexa ” or the “ Company ”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical [...]
BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
22/11/2024
NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines [...]
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
22/11/2024
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today [...]
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
22/11/2024
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One® to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America Meeting
22/11/2024
Early feasibility work demonstrates Focal One system’s ability to generate histotripsy lesions ex vivo LYON, France, November 22, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, [...]
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
22/11/2024
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP, HCM and Obesity Efforts [...]
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
22/11/2024
Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases [...]
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
22/11/2024
CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will [...]
Eyenovia Provides Update on Restructuring Efforts
22/11/2024
Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize [...]
NewGenIvf Receives Nasdaq Delisting Notice and Plans to Submit Appeal, Announces Strategic Path Forward to Regain Compliance
22/11/2024
Multiple strategic initiatives include applying to transfer to Nasdaq Capital Market, leveraging recent fundraising arrangements to boost equity BANGKOK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ [...]
Scilex Holding Company Announces Receipt of Notice from Nasdaq
22/11/2024
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Orion Research Foundation grants EUR 1,109,000 for research in 2025
22/11/2024
Orion Research Foundation grants EUR 1,109,000 for research in 2025 Press release 22 November, 2024 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,109,000 in research grants based on applications for [...]
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
22/11/2024
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex [...]
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
22/11/2024
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the [...]
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
22/11/2024
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began focusing on products [...]
Notice of AGM
22/11/2024
DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of 2024 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event
22/11/2024
MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21 st Virtual [...]
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
21/11/2024
MIPLYFFA, the first FDA-approved treatment for Niemann-Pick disease type C, is available at Zevra’s specialty pharmacy for dispense AmplifyAssist™ , Zevra’s comprehensive patient support program, in place to address [...]

Pages